Drugs / Vintafolide
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | EU (EMA) | — | progesterone-receptor positive breast cancer | 2012-11-27 | “The acceptance of the EMA filing for vintafolide is an important milestone for Merck and Endocyte” merck.com ↗ |
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02049281 | Feb → May 2014 | cancer | Endocyte | Terminated | No outcome recorded |
| Phase 1 | NCT01688791 | Dec 2012 → Sep 2014 | — | Endocyte | Terminated | No outcome recorded |
| Phase 1 | NCT00308269 | Mar 2006 → Aug 2007 | cancer | Endocyte | Completed | No outcome recorded |
| Phase 26 trials · 1 met primary | ||||||
| Phase 2 | NCT01953536 | Apr 2014 → Nov 2016 | breast neoplasm | Endocyte | Withdrawn | No outcome recorded |
| Phase 2 | NCT01577654 | Mar 2011 → Dec 2013 | non-small cell lung carcinoma | Endocyte | Completed | No outcome recorded |
| Phase 2 | NCT01002924 | Dec 2009 → Dec 2013 | cancer | Endocyte | Completed | No outcome recorded |
| Phase 2 | NCT00722592 | Sep 2008 → Sep 2010 | ovarian cancer | Endocyte | Completed | Met primary |
| Phase 2 | NCT00511485 | Aug 2007 → Jul 2009 | lung adenocarcinoma | Endocyte | Completed | No outcome recorded |
| Phase 2 | NCT00507741 | Aug 2007 → Apr 2009 | endometrial cancer, ovarian cancer | Endocyte | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01170650 | Apr 2011 → May 2015 | ovarian cancer | Endocyte | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
All press releases naming this drug 4 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vintafolide | “Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)” NCT01002924 ↗ |
| Known as | EC145 | “Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)” NCT00507741 ↗5“Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)” NCT00511485 ↗ “Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)” NCT00308269 ↗ |
| Known as | MK-8109 | “Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)” NCT00507741 ↗2“Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)” NCT00511485 ↗ “Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01)” NCT00308269 ↗ |
| Known as | Vintafolida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039521 ↗ |
| Modality | Other / unclassified | “EC145 (vintafolide), a conjugate of folic acid and the vinca alkaloid desacetylvinblastine hydrazide (DAVLBH)” PMID 23032618 ↗ Oct 2012 |
| Route | Intravenous | “Vintafolide given by intravenous bolus or infusion” NCT00308269 ↗ |
| Target | FOLR1 | “Folate receptor alpha binding agent” CHEMBL3039521 ↗ |